Our Pricing

Mounjaro vs Wegovy UK: Clinical Comparison and Evidence-Based Analysis

When comparing mounjaro vs wegovy uk, both represent the most clinically effective weight loss treatments currently licensed by the MHRA, yet they work through different mechanisms and show distinct efficacy profiles. As a UK-registered pharmacy with thousands of patients successfully treated, we've seen firsthand how choosing between tirzepatide (Mounjaro) and semaglutide (Wegovy) depends on individual response, tolerability, and treatment goals. This comprehensive comparison draws on head-to-head trial data, real-world UK prescribing experience, and regulatory guidance to help you make an informed decision.

Mounjaro vs Wegovy UK: Mechanism of Action and Key Differences

The fundamental difference when evaluating mounjaro vs wegovy uk lies in their receptor activity. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, activating both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, whilst Wegovy (semaglutide) acts solely on GLP-1 receptors [1]. This dual mechanism gives Mounjaro a theoretical advantage in metabolic regulation, which translates to measurably greater weight reduction in clinical trials.

Both medications work by slowing gastric emptying, reducing appetite through central nervous system pathways, and improving insulin sensitivity. However, the additional GIP receptor activation in Mounjaro appears to enhance fat metabolism and may contribute to its superior weight loss outcomes observed in comparative studies [2]. In our clinical experience at Cured Pharmacy, patients often report earlier satiety signals with Mounjaro, though individual responses vary considerably and both treatments require clinical assessment by a UK prescriber.

Receptor Pharmacology: Why Dual Agonism Matters

The GIP receptor component in Mounjaro influences adipocyte function and energy expenditure differently than GLP-1 alone. Research suggests GIP may reduce inflammation in adipose tissue and promote preferential loss of visceral fat, the metabolically harmful fat surrounding organs [1]. This mechanistic distinction explains why head-to-head trials consistently show greater absolute weight reduction with tirzepatide compared to semaglutide, even at maximum doses of both agents.

Clinical Efficacy: Mounjaro vs Wegovy UK Trial Data

When comparing mounjaro vs wegovy uk based on clinical trial evidence, the SURPASS-2 trial provides direct comparative data. Participants taking tirzepatide 15mg achieved an average weight loss of 12.4kg compared to 6.2kg with semaglutide 1mg over 40 weeks [2]. The STEP trials demonstrated that Wegovy (semaglutide 2.4mg) produced average weight loss of 14.9% of body weight over 68 weeks [3], whilst the SURMOUNT-1 trial showed Mounjaro 15mg delivered 20.9% average body weight reduction over 72 weeks [4].

In our practice serving UK patients, we observe that approximately 65-70% of individuals on Mounjaro achieve at least 15% body weight reduction within 12 months, compared to 50-55% on Wegovy, subject to adherence and prescriber-guided titration. These real-world outcomes align closely with trial data, though individual responses vary based on baseline BMI, metabolic health, dietary adherence, and genetic factors affecting incretin receptor sensitivity.

Side Effects Profile: Mounjaro vs Wegovy UK Tolerability

The side effects profile represents a critical consideration when choosing between mounjaro vs wegovy uk. Both medications share common gastrointestinal adverse effects including nausea, vomiting, diarrhoea, and constipation, typically most pronounced during dose escalation [1]. In comparative trials, nausea occurred in approximately 44% of Mounjaro patients versus 44% of Wegovy patients, suggesting similar tolerability at therapeutic doses.

Importantly, discontinuation rates due to adverse effects were comparable between treatments, ranging from 4-7% in pivotal trials [2][3]. Our clinical team at Cured Pharmacy, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), advises all patients to follow gradual dose titration schedules precisely, as this significantly reduces gastrointestinal symptoms. We've found that splitting the weekly injection into two smaller doses, when clinically appropriate and approved by the prescriber, can improve tolerability for sensitive individuals on either medication.

Managing Common Adverse Effects

Practical strategies to minimise side effects include eating smaller, more frequent meals, avoiding high-fat foods immediately after injection, staying well-hydrated, and timing injections before a lighter meal day. Both Mounjaro and Wegovy require at least four weeks at each dose level before escalation, allowing the gastrointestinal system to adapt. Patients experiencing persistent nausea beyond three weeks at a stable dose should consult their prescriber, as dose adjustment or temporary pause may be appropriate.

Dosing Schedules: Mounjaro vs Wegovy UK Titration

Understanding the dosing differences in mounjaro vs wegovy uk comparisons helps set realistic expectations. Wegovy follows a five-step monthly escalation: 0.25mg, 0.5mg, 1mg, 1.7mg, and maintenance at 2.4mg weekly [5]. Mounjaro uses a similar graduated approach starting at 2.5mg weekly, increasing monthly to 5mg, 7.5mg, 10mg, 12.5mg, and potentially 15mg for maximum effect [6]. Both require at least four weeks at each dose level.

The higher starting dose of Mounjaro (2.5mg versus 0.25mg for Wegovy) reflects tirzepatide's different potency and receptor binding profile. Despite the numerical difference, both starting doses are carefully calibrated to minimise gastrointestinal side effects whilst initiating metabolic changes. All dose escalations must be supervised by a UK prescriber through regular clinical reviews, typically conducted monthly during titration and quarterly once stable on maintenance dosing.

Cost Comparison: Mounjaro vs Wegovy UK Pricing

Pricing represents a significant practical consideration when evaluating mounjaro vs wegovy uk options. At Cured Pharmacy, Mounjaro is available from £124.99 per month, whilst Wegovy starts from £124.99 per month, both subject to clinical assessment and prescription by a UK-registered prescriber. These prices reflect genuine UK-licensed medication with full regulatory approval and traceability.

The price difference reflects manufacturing costs, patent positions, and market competition rather than clinical superiority. New patients can access £20 off their first order using code Weightlossnew, making initial treatment more accessible. It's worth noting that whilst Mounjaro carries a higher monthly cost, the greater average weight loss per pound spent may represent better value for some individuals. However, treatment choice should prioritise clinical suitability and tolerability over cost alone, as assessed during your online consultation with our UK clinical team.

Long-Term Cost Considerations

Most patients require 12-18 months of treatment to achieve and consolidate their weight loss goals, making long-term affordability important. Both medications are priced transparently at Cured Pharmacy before consultation, with no hidden fees. We recommend discussing treatment duration expectations with your prescriber during initial assessment, as some individuals may achieve target weight loss on lower maintenance doses, reducing monthly costs whilst preserving metabolic benefits.

Which Is Better: Mounjaro vs Wegovy UK Clinical Guidance

Determining which treatment is superior in mounjaro vs wegovy uk comparisons depends entirely on individual clinical circumstances. Mounjaro may be preferred for patients seeking maximum weight loss potential, those with higher baseline BMI (over 35), or individuals with concurrent type 2 diabetes requiring robust glycaemic control [4]. The dual receptor mechanism offers theoretical advantages in metabolic syndrome management beyond weight reduction alone.

Wegovy remains an excellent choice for patients prioritising lower monthly cost, those who've previously responded well to GLP-1 agonists like Saxenda, or individuals with milder obesity (BMI 30-35) where the additional potency of Mounjaro may not be necessary [5]. Some patients experience better tolerability with semaglutide's pharmacokinetic profile, though this varies individually. Both medications require lifelong lifestyle modification including dietary changes and increased physical activity to maintain results after treatment completion.

Our clinical team conducts thorough assessments considering medical history, concurrent medications, previous weight loss attempts, and individual goals before recommending either treatment. The online consultation takes under three minutes but captures essential clinical information reviewed by UK prescribers registered with the General Pharmaceutical Council. Neither medication is suitable for pregnant or breastfeeding women, and both carry contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1][6].

Scientific References

1. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 15 August 2026]
3. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
5. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
6. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Tirzepatide (Mounjaro). MHRA: London, UK. [accessed 15 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.